The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Upcoming NCRI AML subgroup trials
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the key news and updates from the NCRI acute myeloid leukemia (AML) subgroup, including the EVOLVE study investigating the benefit of adding a FLT3 inhibitor into a venetoclax regimen in older unfit acute myeloid leukemia (AML) by Paresh Vyas and Mike Dennis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
